Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, and development of branded pharmaceutical products. The Company markets a portfolio of branded products, including: TREXIMET®, SILENOR®, a non-narcotic product indicated for the treatment of
insomnia characterized by difficulties with sleep maintenance, KHEDEZLA™, as well as CEDAX®, an antibiotic for middle ear infections. The Company promotes its branded products to physicians through its Pernix sales force and distributes its generic portfolio through its wholly owned subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals. Founded in 1996, the Company is based in Morristown, New Jersey.
Pernix Therapeutics Closes on Acquisition of Treximet. Raises $220m Senior Notes. Issues Updated 2014 Guidance.
PERNIX THERAPEUTICS REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS
Closing for PERNIX transaction to acquire TREXIMET® Tablets for Migraine from GSK Delayed
Pernix Therapeutics’ family of branded prescription products are well-recognized and a highly prescribed portfolio of core marketed products. Our products are developed to meet the needs of patients and physicians by focusing on safe, unique and effective products for treating common medical conditions.
Pernix distributes its generic products through its wholly-owned subsidiaries, Macoven Pharmaceuticals and Cypress Pharmaceutical. The generic product portfolios include the areas of antibiotics, respiratory care, dermatology, pain, gastroenterology, dental health and vitamins.